---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-038328"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2023-08-04T23:59:59+00:00"
generated_at: "2026-06-12T05:47:29.838863+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences Q2 net loss narrows to $11.9M; FDA clarity on azer-cel; cash through Q1 2025

## Summary
- Net loss of $11.9M ($0.10 per share) vs $31.0M ($0.46) in Q2 2022; revenue $19.8M from $3.8M on Prevail amendment.
- Cash and equivalents $137.8M; expected runway through Q1 2025 without additional funding.
- FDA Type B meeting provided clarity on azer-cel registration path; partnering discussions underway for cell therapy assets.
- In vivo gene editing programs progressing: PBGENE-HBV plans IND/CTA in 2024; PBGENE-DMD shows proof-of-concept; Novartis and Prevail collaborations ongoing.
- Company to host In Vivo Gene Editing R&D Day on September 12, 2023.

## SEC filing metadata
- accession: 0000950170-23-038328
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2023-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017023038328/0000950170-23-038328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017023038328/dtil-20230804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-038328
- JSON: https://secwatch.observer/filing/0000950170-23-038328.json
- Plain text: https://secwatch.observer/filing/0000950170-23-038328.txt

## Key facts
- Earnings Releases
  PRECISION BIOSCIENCES INC reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 4, 2023, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357874/000095017023038328/0000950170-23-038328-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.